Patients with MSMD due to other inborn errors impairing the production of IFN-γ, such as IL-12p40 and IL-12Rβ1 deficiencies, have been shown to benefit from IFN-γ1b therapy [28, 34–40]. This evidence concerns the gene IL12RB1 and Mendelian susceptibility to mycobacterial diseases.